AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2212123
Drug: Intradermal platelet-activating
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal platelet-activating factor (PAF-acether)
Trial: 2212123
Drug: Platelet activating
RxNorm normalized name: Platelet activating factor
DrugBank: Platelet Activating Factor (DB02261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet activating factor antagonist BN52063
Trial: 81986
Drug: Control tablet
RxNorm normalized name: Daily-Vite Weight Control Tablet
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control tablet substituted
Trial: 28526014
Drug: Antihyperglycaemia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihyperglycaemia therapy
Trial: 16981050
Drug: Rheumazin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumazin (10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine, 2.5 mg cyanocobalamin)
Trial: 16981050
Drug: Feldene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feldene (20 mg piroxicam)
Trial: 12428781
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for depression (CBT-D)
Trial: 28864706
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation treatment
Trial: 2221287
Drug: Hazelden‐type treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelden‐type treatment (N = 74)
Trial: 2221287
Drug: Traditional‐type treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional‐type treatment (N = 67)
Trial: 349319
Drug: Labetalol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (600 mg twice a day)
Trial: 349319
Drug: Prindolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prindolol (15 mg twice a day) plus Hydralazine (50 mg three times a day)
Trial: 30028640
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of itraconazole 100 mg
Trial: 30028640
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of itraconazole 100 mg
Trial: 19602188
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) treatment: three sets of 60 s of vibration (30 Hz, +/-4 mm) while standing in a semi-squat position
Trial: 19602188
Drug: Control treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment: static squat
Trial: 2197898
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg induction and 0.15 mg/kg per min maintenance with N2O/O2
Trial: 2197898
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg induction and enfluran maintenance with N2O/O2
Trial: 921082
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients
Trial: 921082
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to controls
Trial: 921082
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients at the time of chemotherapy
Trial: 921082
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients between chemotherapy courses
Trial: 31331617
Drug: LSD 6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 6.5 μg
Trial: 31331617
Drug: LSD 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 13 μg
Trial: 31331617
Drug: LSD 26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 26 μg
Trial: 31331617
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 μg)
Trial: 23855816
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 30 g/day
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 60 g/day
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 80 g/day
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 10 g/day
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB 15 g/day
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB (all doses)
Trial: 15220947
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB (up to 45 g/day)
Trial: 11898516
Drug: Various tic-suppressing
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various tic-suppressing treatments including hydrotherapy, behavioral treatments, pharmacotherapy, botulinum toxin, immunomodulatory therapy, and surgery; specific dosages and durations not available.
Trial: 9850434
Drug: Patented soft
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patented soft gelatine capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Trial: 9850434
Drug: Hard shell
RxNorm normalized name: Hard Gelatin Capsule Shell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard shell capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Trial: 8115666
Drug: Piroxicam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (40 mg, intramuscular injection)
Trial: 8115666
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (500 mg, intravenous injection)
Trial: 8115666
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg, intravenous injection)
Trial: 19650782
Drug: Levothyroxine (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (64 nmol) and Liothyronine (16 nmol) supplement
Trial: 19816018
Drug: Neuroaid (MLC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroaid (MLC 601), 4 capsules 3 times a day for 4 weeks
Trial: 19816018
Drug: Placebo, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 4 capsules 3 times a day for 4 weeks
Trial: 16621658
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist (DA) monotherapy
Trial: 15599534
Drug: CO2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CO2 therapy after liposuction (2 weekly applications for 10 weeks)
Trial: 15599534
Drug: CO2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CO2 therapy alone (2 weekly applications for 10 weeks)
Trial: 9483214
Drug: L‐myc oncoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐myc oncoprotein
Trial: 10562823
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg base/kg body weight over 3 days)
Trial: 8311568
Drug: Amodiaquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (25 mg base/kg body weight over 3 days)
Trial: 8311568
Drug: Quinine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (8 mg/kg every 8 h for 3 or 5 days)
Trial: 8311568
Drug: Sulphadoxine-pyrimethamine (25-1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadoxine-pyrimethamine (25-1.25 mg/kg, in one dose)
Trial: 29521887
Drug: Team-Based Learning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team-Based Learning (TBL), 6 hours (2 hours weekly for 3 weeks)
Trial: 29521887
Drug: Lecture-style classes,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecture-style classes, 6 hours (2 hours weekly for 3 weeks)
Trial: 24676848
Drug: Low-magnitude high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-magnitude high-frequency vibration (LMHFV) - 20 min daily, 35 Hz, 0.3 g, 5 days/week for 18 months
Trial: 18800460
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg
Trial: 7583899
Drug: Clonidine-bupivacaine-morphine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine-bupivacaine-morphine
Trial: 7583899
Drug: Bupivacaine-morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-morphine
Trial: 19181448
Drug: Any type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any type of opioid prescriptions for >or=90 days
Trial: 19181448
Drug: No opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No opioid prescriptions
Trial: 17188618
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids and oral cyclophosphamide (CYC) (maximum total dose 150 mg/kg) followed by oral methotrexate (MTX) (12.5 mg/m(2)/week) for maintenance.
Trial: 17188618
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids and methotrexate (MTX) (12.5 mg/m(2)/week).
Trial: 10856105
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alfa-2b (HDI) for 1 year
Trial: 11331315
Drug: GM2 conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GM2 conjugated to keyhole limpet hemocyanin and administered with QS-21 (GMK) for 96 weeks
Trial: 9205817
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of zolmitriptan (3.5 mg)
Trial: 9205817
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet of zolmitriptan (10 mg)
Trial: 9205817
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 25 mg [14C]-zolmitriptan capsule
Trial: 9205817
Drug: Intravenous dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dosing of zolmitriptan
Trial: 8434963
Drug: NK 622
RxNorm normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK 622 (toremifene citrate) 40 mg/day
Trial: 23410986
Drug: VES‐ODT (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VES‐ODT (orally disintegrating tablet)
Trial: 23410986
Drug: VES‐CT (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VES‐CT (conventional tablet)
Trial: 14998427
Drug: 3-day training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day training program on rational pharmacotherapy
Trial: 11463766
Drug: Angiotensin-(1-7) infusion
RxNorm normalized name: Angiotensin (1-7)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-(1-7) infusion (10(-10), 10(-9), and 10(-8) mol/min for 5 minutes)
Trial: 11463766
Drug: N(G)-monomethyl-L-arginine (nitric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (nitric oxide synthesis inhibitor)
Trial: 2567745
Drug: Performance-based treatment
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance-based treatment for some phobic areas
Trial: 4909766
Drug: High oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oral doses of marihuana extract (1 (‐)‐Delta(1)‐tetrahydrocannabinol)
Trial: 28025037
Drug: Inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin with azithromycin
Trial: 28025037
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam after tobramycin
Trial: 28025037
Drug: Inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin without azithromycin
Trial: 21248785
Drug: Amlodipine/valsartan/hydrochlorothiazide (10/320/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg)
Trial: 21248785
Drug: Dual therapies
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapies (valsartan/hydrochlorothiazide, amlodipine/valsartan, amlodipine/hydrochlorothiazide)
Trial: 17971827
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (30 mg) with micronutrients
Trial: 17971827
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (30 mg) without micronutrients
Trial: 17380489
Drug: 10 cm2
RxNorm normalized name: thrombin/cal/cmc/gel/dress,hem 10 cm2 TOPICAL PADS, MEDICATED (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cm2 rivastigmine patch
Trial: 17380489
Drug: 20 cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 cm2 rivastigmine patch
Trial: 21309961
Drug: 12 mg/day
RxNorm normalized name: EMSAM 12 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/day rivastigmine capsules
Trial: 17380489
Drug: All patch
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patch sizes (5, 10, 15, and 20 cm2)
Trial: 7836964
Drug: Chlorpromazine (CHLP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CHLP, 50 mg, i.m.)
Trial: 3354865
Drug: Nalbuphine hydrochloride
RxNorm normalized name: Nalbuphine Hydrochloride
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine hydrochloride 0.2 mg/kg
Trial: 26599904
Drug: Icotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg tablet, three times per day)
Trial: 12858462
Drug: 20 micro
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micro g of teriparatide by daily self-injection
Trial: 12858462
Drug: 40 micro
RxNorm normalized name: Travoprost 40 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micro g of teriparatide by daily self-injection
Trial: 7753338
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) infusion (1 microgram/kg/h) with metyrapone
Trial: 30184222
Drug: Complementary food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary food supplements (CFSs)
Trial: 27297847
Drug: Eliminating patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliminating patient copayment for P2Y12 receptor inhibitor therapy
Trial: 24685421
Drug: Offer of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Offer of treatment by a homeopath
Trial: 8980935
Drug: RAT2 (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAT2 (ranitidine 300 mg twice daily, amoxycillin 1000 mg twice daily, plus tinidazole 500 mg twice daily for 2 weeks)
Trial: 8980935
Drug: RA2 (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA2 (ranitidine 300 mg twice daily plus amoxycillin 1000 mg twice daily for 2 weeks)
Trial: 1727754
Drug: Tube-fed nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tube-fed nutrition (1.5 g/kg protein and 167 kJ/kg daily)
Trial: 25967526
Drug: Travoprost 0.004%
RxNorm normalized name: TRAVOPROST 0.004% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004% preserved with SofZia (TRAVATAN Z solution)
Trial: 21987393
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a (immediate-treatment group)
Trial: 21987393
Drug: Placebo (delayed-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (delayed-treatment group)
Trial: 17873022
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion at a rate of 5 pmol/kg per minute for 180 min
Trial: 10512130
Drug: Paclitaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (60 mg/m2) given as a 3‐h infusion on days 1, 8, 15, 22, 29 and 36; CHART started on day 15 with 150 cGy/fraction given three times a day for a total dose of 54 Gy in 12 days.
Trial: 7555483
Drug: Programmable implantable
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmable implantable pump therapy
Trial: 6113885
Drug: Fazadinium bromide
RxNorm normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium bromide 1 mg . kg‐1
Trial: 6113885
Drug: Fazadinium bromide
RxNorm normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium bromide 1.5 mg . kg‐1
Trial: 20236365
Drug: Uridine (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine (36 g tid on 10 consecutive days per month; n=10)
Trial: 20236365
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg nocte; n=12)
Trial: 17401044
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg dexamethasone suppression test
Trial: 15707766
Drug: Saffron 30
RxNorm normalized name: SAFFRON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron 30 mg/day (BD)
Trial: 15707766
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day (BD)
Trial: 12123331
Drug: IRIFAFU (Irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRIFAFU (Irinotecan 200 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 850 mg/m2)
Trial: 12123331
Drug: MTXFAFU (Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTXFAFU (Methotrexate 750 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 800 mg/m2)
Trial: 20937929
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated equine estrogens (CEE)
Trial: 8569016
Drug: E+P regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E+P regimens (0.625 mg/d of CEE plus 10 mg/d of MPA for the first 12 days, 0.625 mg/d of CEE plus 2.5 mg/d of MPA, or 0.625 mg/d of CEE plus 200 mg/d of MP for the first 12 days)
Trial: 8569016
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of CEE
Trial: 6122852
Drug: 2% phenoxetol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% phenoxetol and 0.2% chlorhexidine cream
Trial: 17559733
Drug: Sitagliptin 25
RxNorm normalized name: SITagliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 25 mg once-daily
Trial: 17559733
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg once-daily
Trial: 17130197
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once-daily
Trial: 17559733
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg twice-daily
Trial: 8917000
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 micrograms
Trial: 11207490
Drug: Intravenous syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous syntocinon 10 IU
Trial: 8042809
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (360 micrograms)
Trial: 8042809
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol and ipratropium bromide
Trial: 24152211
Drug: Bronchodilator treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator treatment
Trial: 21067350
Drug: ceftaroline 600
RxNorm normalized name: ceftaroline 600 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftaroline 600 mg every 12 h for 5-7 days